Vivodyne unveils the world’s largest biological datacenter

California startup Vivodyne said today that it has built what it calls the world’s largest biological datacenter, a robotic drug-testing setup that screens medicines on lab-grown human tissue rather than leaning so heavily on mice and dogs.

The company says the platform brings together software, robotics, and more than 20 tissue types, including liver, lung, and bone marrow, across 12 HIVE labs. The idea is to test safety and efficacy at a scale of about 3.1 million tissues per year, which Vivodyne says is roughly twice the scale of all U.S. clinical trials combined.

Vivodyne’s argument is straightforward: 90% to 95% of drugs that look successful in animal tests still fail in humans. If those failures can be spotted earlier with human tissue models, that could improve the pool of drugs that make it into human trials. The push also lines up with broader moves across the industry, including work from Emulate, CN Bio, and Hesperos, along with backing from the U.S. Food and Drug Administration after the 2022 Modernization Act 2.0.

If you track drug development, this is a platform to keep an eye on. It still doesn’t replace animal testing outright, though, because drug developers need whole-body biology too, including immune interactions, blood flow, and system-wide drug effects.

Vivodyne also says it has raised $79.6 million, including a $40 million Series A led by Khosla Ventures in May 2025, and that its expanded work will operate out of a new 23,000-square-foot lab in South San Francisco.